April 2024 Patent Highlights: GPR84 Antagonists, TYK2 Inhibitors, JAK2 V617F Inhibitors, and More!

Here’s a quick recap of the top business news from October, including major deals, acquisitions, funding rounds, and strategic partnerships. If you missed any updates, here’s your chance to catch up on the most significant developments in the industry.

In this article, we present a curated selection of over 60 molecules from September that caught our attention, along with highlights of our top picks and insights into why they stand out.

Check out our searchable, annotated database featuring our curated selection of the most important drug discovery patents published in October 2024.

This article highlights a patent application from Arvinas that discloses the biological activity of compounds that act as tau-targeting heterobifunctional degraders, providing a summary of key data for selected molecules disclosed in the patent application.

This article highlights a patent application from Monte Rosa Therapeutics that discloses the biological activity of compounds that act as VAV1 molecular glue degraders, providing a summary of key data for selected molecules disclosed in the patent application.